信迪利单抗联合安罗替尼治疗三线及以上肺腺癌患者的临床疗效

目的:观察信迪利单抗联合安罗替尼用于治疗三线及以上晚期肺腺癌的临床疗效和不良反应。方法:将自2019年3月至2020年8月在本院肿瘤科进行诊治的118例晚期肺腺癌患者分为安罗替尼组（n=59）和联合治疗组（n=59），分别采用安罗替尼单药，信迪利单抗联合安罗替尼进行治疗，采用胸部计算机断层扫描放射，计算机断层扫描，骨扫描等检测患者肿瘤进展，治疗前后采用TDL生命质量测定表(TDL-QOLAS)反映患者生命质量水平，通过酶联免疫吸附法测量血液肿瘤标志物水平，此外，在随访截至时使用Morisky药物依从性量表评估所有患者服药依从性，通过Kaplan-Meier曲线描述两组患者的PFS（无病进展期）和OS（总生存期），并观察用药期间两组患者不良反应发生情况。结果:联合治疗组的ORR、PFS和OS均明显高于安罗替尼组，分别为23.7% vs 10.2%、6.9个月vs 4.7个月、15.7个月vs 9.3个月，差异有统计学意义（P＜0.05）。血液学分析显示，联合治疗与安罗替尼单用均可显著降低血清肿瘤标志物水平，而联合治疗效果更佳（P＜0.05），此外，相较于安罗替尼单药组，联合治疗可以更好的提高患者生活质量并具有良好的用药依从性（P＜0.05），且联合治疗组未明显增加治疗相关不良反应，未发生因不良反应终止治疗的事件，无治疗相关死亡事件。结论:信迪利单抗联合安罗替尼治疗三线及以上肺腺癌患者，可显著改善患者的生存时间，具有良好的用药依从性和安全性，值得临床进一步推广。

Clinical efficacy of sinotilimab combined with anlotinib in patients with third-line and above lung adenocarcinoma

Objective:To observe the clinical efficacy and adverse reactions of sinotilimab combined with anlotinib for the treatment of advanced third-line and advanced lung adenocarcinoma.Methods:The 118 patients with advanced lung adenocarcinoma diagnosed and treated in our oncology department from March 2019 to August 2020 were divided into anlotinib(n=59) and combined treatment group (n=59),respectively taking anlotinib,sintilimab combined with anlotinib for treatment,using chest computed tomography radiography,computed tomography,bone scan,to detect the patient's tumor progression,before and after treatment,using the TDL quality of life table (TDL-QOLAS) reflects the quality of life of patients.Using enzyme-linked immunosorbent assay to detect the level of blood tumor markers.In addition,at the end of follow-up,Morisky drug compliance scale was used to assess the compliance of all patients,the Kaplan-Meier curve was used to describe the PFS (progression-free period) and OS (overall survival period) of the two groups of patients,and observes the occurrence of adverse reactions during the treatment of the two groups of patients.Results:The ORR,PFS and OS of the combination therapy group were significantly higher than those of the anlotinib group,respectively 23.7% vs 10.2%,6.9 months vs 4.7 months,15.7 months vs 9.3 months,the difference was statistically significant (P＜0.05).Hematological analysis showed that combination therapy and anlotinib alone can significantly reduce serum tumor marker levels,and the combination therapy was more effective (P＜0.05).In addition,compared with the anlotinib monotherapy group,the combination treatment could better improve the patient's quality of life and had good medication compliance (P＜0.05),and the combination treatment group did not significantly increase treatment-related adverse reactions,no event of termination of treatment due to adverse reactions,and no treatment-related deaths.Conclusion:Sintilimab combined with anlotinib in the treatment of patients with more than third-line lung adenocarcinoma can significantly improve the survival time of patients,has good medication compliance and safety,and is worthy of further clinical promotion.